NASDAQ:NXTM NxStage Medical (NXTM) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free NXTM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$29.98▼$30.0050-Day Range$30.00▼$30.0052-Week Range$23.17▼$30.00Volume2.61 million shsAverage Volume1.51 million shsMarket Capitalization$2.00 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get NxStage Medical alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About NxStage Medical Stock (NASDAQ:NXTM)NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.Read More Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. NXTM Stock News HeadlinesJuly 21, 2023 | wsj.comNextcom Ltd.September 23, 2022 | reuters.comNXTM.TA - Nextcom Ltd. | Stock Price & Latest News | ReutersMay 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. October 26, 2021 | finance.yahoo.comOmnicell to Buy Ateb, Expand in Adherence Tools MarketSee More Headlines Receive NXTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NxStage Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2017Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:NXTM CUSIP67072V10 CIK1333170 Webwww.nxstage.com Phone978-687-4700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,470,000.00 Net Margins-1.29% Pretax MarginN/A Return on Equity-2.50% Return on Assets-1.60% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio2.69 Sales & Book Value Annual Sales$393.94 million Price / Sales5.08 Cash Flow$0.29 per share Price / Cash Flow103.07 Book Value$3.22 per share Price / Book9.32Miscellaneous Outstanding Shares66,680,000Free FloatN/AMarket Cap$2.00 billion OptionableOptionable Beta0.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jeffrey H. Burbank (Age 56)Founder, CEO & Director Mr. Joseph E. Turk Jr. (Age 51)Pres Mr. Matthew W. Towse (Age 56)Sr. VP, CFO & Treasurer Ms. Winifred L. Swan (Age 55)Sr. VP, Gen. Counsel & Sec. Dr. Allan J. CollinsHead of Scientific Advisory Board & Chief Medical OfficerKey CompetitorsIntegerNYSE:ITGRMasimoNASDAQ:MASICONMEDNYSE:CNMDSoleno TherapeuticsNASDAQ:SLNOInModeNASDAQ:INMDView All Competitors NXTM Stock Analysis - Frequently Asked Questions How were NxStage Medical's earnings last quarter? NxStage Medical, Inc. (NASDAQ:NXTM) released its quarterly earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.00. The medical device company had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 1.29% and a negative trailing twelve-month return on equity of 2.50%. NxStage Medical's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) EPS. What other stocks do shareholders of NxStage Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other NxStage Medical investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ). This page (NASDAQ:NXTM) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NxStage Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.